These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 36043877

  • 1. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies).
    Hernández-García M, García-Castillo M, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Cruz H, Chaves C, Duarte J, Pássaro L, Díaz-Regañón J, Cantón R.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0292722. PubMed ID: 36043877
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies).
    Hernández-García M, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Cruz H, Chaves C, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Díaz-Regañón J, Pássaro L, Duarte J, Cantón R, STEP and SUPERIOR study groups.
    J Antimicrob Chemother; 2022 Oct 28; 77(11):3163-3172. PubMed ID: 36059128
    [Abstract] [Full Text] [Related]

  • 3. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
    Cabello M, Hernández-García M, Maruri-Aransolo A, Michelena M, Pérez-Viso B, Ponce-Alonso M, Cantón R, Ruiz-Garbajosa P.
    J Glob Antimicrob Resist; 2024 Sep 28; 38():281-291. PubMed ID: 38996870
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A, Study Collaborators.
    Eur J Clin Microbiol Infect Dis; 2019 Jun 28; 38(6):1143-1150. PubMed ID: 30825054
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS, Baek JY, Ko J-H, Cho SY, Lee KY, Lee YH, Yang J, Kim TY, Huh HJ, Lee NY, Huh K, Kang C-I, Chung DR, Peck KR.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0034424. PubMed ID: 38687076
    [Abstract] [Full Text] [Related]

  • 6. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M, García-Fernández S, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Costa E, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva T, Chaves C, Pássaro L, Paixão L, Romano J, Cantón R, STEP study group.
    Int J Antimicrob Agents; 2021 Feb 04; 57(2):106259. PubMed ID: 33310115
    [Abstract] [Full Text] [Related]

  • 7. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S, Mavromanolaki VE, Magkafouraki E, Moraitis P, Stafylaki D, Kasimati A, Scoulica E.
    Infection; 2022 Apr 04; 50(2):467-474. PubMed ID: 34854060
    [Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.
    Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Cantón R.
    Antimicrob Agents Chemother; 2022 Mar 15; 66(3):e0216121. PubMed ID: 35007130
    [Abstract] [Full Text] [Related]

  • 9. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 15; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 10. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
    Delgado-Valverde M, Portillo-Calderón I, Alcalde-Rico M, Conejo MC, Hidalgo C, Del Toro Esperón C, Pascual Á.
    Eur J Clin Microbiol Infect Dis; 2024 Mar 15; 43(3):445-457. PubMed ID: 38157139
    [Abstract] [Full Text] [Related]

  • 11. Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales.
    Vázquez-Ucha JC, Seoane-Estévez A, Rodiño-Janeiro BK, González-Bardanca M, Conde-Pérez K, Martínez-Guitián M, Alvarez-Fraga L, Arca-Suárez J, Lasarte-Monterrubio C, Gut M, Gut I, Álvarez-Tejado M, Oviaño M, Beceiro A, Bou G, GEMARA-SEIMC/REIPI Enterobacterales Study Group.
    J Antimicrob Chemother; 2021 May 12; 76(6):1498-1510. PubMed ID: 33677560
    [Abstract] [Full Text] [Related]

  • 12. Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
    Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Vagnone PS, Witwer M, Castanheira M, Johnson JR.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32152073
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM, Antochevis LC, Magagnin CM, Arns B, Vieceli T, Pereira DC, Lutz L, de Souza ÂC, Dos Santos JN, Guerra RR, Medeiros GS, Santoro L, Falci DR, Rigatto MH, Barth AL, Martins AF, Zavascki AP.
    J Glob Antimicrob Resist; 2024 Sep 21; 38():247-251. PubMed ID: 38936472
    [Abstract] [Full Text] [Related]

  • 14. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH.
    Antimicrob Agents Chemother; 2017 Sep 21; 61(9):. PubMed ID: 28630202
    [Abstract] [Full Text] [Related]

  • 15. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M.
    Int J Antimicrob Agents; 2024 Apr 21; 63(4):107113. PubMed ID: 38354826
    [Abstract] [Full Text] [Related]

  • 16. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V, Principe L, Andriani L, Aiezza N, Coppi M, Ricci S, Giani T, Luzzaro F, Rossolini GM.
    Clin Microbiol Infect; 2023 Apr 21; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
    Nordmann P, Bouvier M, Poirel L.
    Eur J Clin Microbiol Infect Dis; 2023 Sep 21; 42(9):1145-1152. PubMed ID: 37566365
    [Abstract] [Full Text] [Related]

  • 18. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, van Duin D, Kreiswirth BN, Kaye KS, Bonomo RA.
    Antimicrob Agents Chemother; 2018 Jun 21; 62(6):. PubMed ID: 29610205
    [Abstract] [Full Text] [Related]

  • 19. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020.
    García-Fernández S, Calvo J, Cercenado E, Suárez-Barrenechea AI, Fernández-Billón M, Castillo FJ, Gálvez-Benítez L, Tubau F, Figueroa Cerón RE, Hernández-Cabezas A, González Romo F, Fariñas MC, Gómez M, Díaz-Regañón J, Cantón R.
    Rev Esp Quimioter; 2023 Jun 21; 36(3):302-309. PubMed ID: 36951688
    [Abstract] [Full Text] [Related]

  • 20. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates.
    Shortridge D, Kantro V, Castanheira M.
    Microbiol Spectr; 2023 Feb 14; 11(1):e0450722. PubMed ID: 36622238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.